Ascendis Pharma A/S (ASND) Stock
ASND Key Statistics
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
CEO: Jan Moller Mikkelsen. Company website
ASND — Frequently Asked Questions
What is the ASND stock price today?
Ascendis Pharma A/S (ASND) trades at $259.28, up 1.05% on the day, as of Nov 12, 2026 09:30 UTC.
What is Ascendis Pharma A/S's market cap?
Ascendis Pharma A/S has a market capitalisation of $17.06B, calculated from the live ASND share price and shares outstanding.
What is the P/E ratio of ASND?
ASND trades at a trailing P/E of 22.64, from earnings per share of $11.45 over the last twelve months.
How much revenue does Ascendis Pharma A/S make?
Ascendis Pharma A/S generated revenue of $1.05B over the trailing twelve months, which puts the stock at 16.18 times sales.
What is the 52-week range for ASND?
ASND has traded between $188.07 and $282.15 over the past 52 weeks, and the last price is 8.1% below that high.
Is Ascendis Pharma A/S profitable?
Yes. Ascendis Pharma A/S keeps 71.69% of revenue as net income over the trailing twelve months.
What is the analyst price target for ASND?
Wall Street analysts rate ASND Buy, with an average price target of $306.33, 18.1% above the current price.
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in DK.
Who is the CEO of Ascendis Pharma A/S?
Jan Moller Mikkelsen is the chief executive of Ascendis Pharma A/S, which employs 1,189 people.
Where can I track ASND in real time?
QFI Terminal shows ASND with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ASND live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ASND in Terminal See plans